Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017/07/01 by P.E. Postmus, K.M. Kerr, M. Oudkerk +5 · 1 citation

paper · doi:10.1093/annonc/mdx222

Cited by

• ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach